ARGNF News and Press, Argen X NV From 11/27/23

2023-11-27 11:04:09 ET Summary argenx's Q3 earnings exceeded expectations, with Vyvgart sales beating by 11%, indicating strong market demand. The anticipated approval for Vyvgart in CIDP by H2 2024 suggests continued positive sales growth. argenx's robust cash position, incre...

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enable broad access to VYVGART SC for eligible patients Amsterdam, The Netherl...

2023-11-05 10:45:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Global Advantage Fund lost 6.1% in Q3 2023, underperforming its benchmarks. ...

2023-11-05 05:45:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Fifth Avenue Growth Fund lost 3.5% in Q3, in line with benchmarks. Fundament...

2023-11-04 11:35:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund declined 6.98% in Q3 2023, underperforming the benchma...

2023-11-04 10:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund fell 5.03% in Q3, slightly underperforming the broader market. ...

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia gravis (gMG) Patients treated with VYVGART experienced consistent improvements ...

2023-10-31 15:32:10 ET argenx SE (ARGX) Q3 2023 Earnings Conference Call October 31, 2023, 08:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Karen Massey - COO ...

2023-10-31 02:16:01 ET More on Argenx SE argenx: Efgartigimod Is Not Just A Drug, A Cornerstone argenx: Three Important Milestones Reached In 2023, More To Come Immunovant drives OmniAb higher after data update; argenx slips Seeking Alpha’s Quant Ratin...

$329 million in third quarter global net product sales On track to submit VYVGART ® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host conference call today at 1:30 pm CET (8:30 am ET) ...